Immunity and Immunotherapy in Inflammatory Bowel Diseases (IBD)
Mechanisms and Innovations
- 1st Edition - November 22, 2026
- Latest edition
- Editors: Deepa S. Mandlik, Satish Mandlik
- Language: English
Covers detailed disease mechanisms and the full spectrum of immune cell biology, through to advanced clinical applications The book highlights the latest advances in immunotherapy,… Read more
Description
Description
Covers detailed disease mechanisms and the full spectrum of immune cell biology, through to advanced clinical applications The book highlights the latest advances in immunotherapy, including cell-based and next-generation treatments. Immunity and Immunotherapy in Inflammatory Bowel Diseases (IBD): Mechanisms and Innovations bridges laboratory research with clinical practice, addressing diagnostics, biomarkers and real-world patient care. It tackles current challenges in IBD, such as therapy resistance, the integration of AI and multi-omic approaches. What sets this book apart is its extensive, up-to-date coverage of all immunotherapeutic strategies, such as monoclonal antibodies, cytokine inhibitors, JAK inhibitors, cell-based therapies, and novel targets such as CAR-T cells and immune checkpoint modulators. It also addresses emerging technologies, personalized medicine, resistance mechanisms, safety, and the gut microbiome, providing a holistic view of current and future directions in IBD immunotherapy.
Key features
Key features
- Written and edited by experts in the field, ‘Immunity and Immunotherapy in Inflammatory Bowel Diseases (IBD): Mechanisms and Innovations’ provides comprehensive insights into the immunopathogenesis of IBD
- Offers detailed descriptions of both established and emerging immunotherapies
- Provides a single resource for crucial information on IBD immunity and immunotherapy, from the molecular factors involved to treatment prospects and future directions
- Provides an extensive, up-to-date coverage of all immunotherapeutic strategies, such as monoclonal antibodies, cytokine inhibitors, JAK inhibitors, cell-based therapies, together with novel targets such as CAR-T cells and immune checkpoint modulators
Readership
Readership
Senior students and academics in healthcare, pharmacy, regulatory affairs, precision medicine and immunotherapy
Table of contents
Table of contents
Part 1 Immunity in inflammatory bowel diseases
1 Overview of inflammatory bowel diseases: from bench to bedside
2 Pathophysiology of inflammatory bowel disease: innate immune system
3 Understanding the intestinal epithelial barrier in IBD
4 Role of innate and adaptive immunity in IBD
5 Role of dendritic cells in pathogenesis of IBD
6 Potential role of natural killer cells in pathogenesis of inflammatory bowel disease
7 Immunobiology of T-Cells and B-Cells in inflammatory bowel disease
8 Immunobiology of intestinal epithelial cells in inflammatory bowel disease
9 Immunobiology of monocytes, macrophages, and polymorphonuclear Cells (PMN) in inflammatory bowel disease
10 Cytokine networks in the pathophysiology of inflammatory bowel disease
11 Role of chemokines in the pathophysiology of inflammatory bowel disease
12 Transforming growth factor (TGF)-β, activins and follistatin: A key regulator in inflammatory bowel disease 14 Role of Occludin, Claudin-2, and Zonulin in inflammatory bowel disease
Part B Immunotherapy in inflammatory bowel diseases
15 Basics of immunotherapy in inflammatory bowel disease
16 Targeting tumor necrosis factor (TNF)-alpha in inflammatory bowel disease
17 Integrin inhibition in inflammatory bowel disease
18 Janus kinase (JAK) inhibitors in inflammatory bowel disease
19 Stem cell and cell-based therapies in inflammatory bowel disease
20 Interleukin inhibition: targeting cytokine pathways
21 Key molecular targets for antisense therapy in inflammatory bowel disease
22 Therapeutic approaches targeting sphingolipids in inflammatory bowel disease
23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets
23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets
24 Immune checkpoint modulation as a therapeutic strategy in inflammatory bowel disease
25 Potential targets for chimeric antigen receptor (CAR)-T cells in inflammatory bowel disease
26 Personalized medicine in inflammatory bowel disease immunotherapy
27 Advances in immunotherapy and emerging agents
28 Immunotherapy resistance and management of failure in inflammatory bowel disease
29 Safety, long-term outcomes, and side effects of immunotherapy
30 Immunotherapy and the gut microbiome in inflammatory bowel disease
1 Overview of inflammatory bowel diseases: from bench to bedside
2 Pathophysiology of inflammatory bowel disease: innate immune system
3 Understanding the intestinal epithelial barrier in IBD
4 Role of innate and adaptive immunity in IBD
5 Role of dendritic cells in pathogenesis of IBD
6 Potential role of natural killer cells in pathogenesis of inflammatory bowel disease
7 Immunobiology of T-Cells and B-Cells in inflammatory bowel disease
8 Immunobiology of intestinal epithelial cells in inflammatory bowel disease
9 Immunobiology of monocytes, macrophages, and polymorphonuclear Cells (PMN) in inflammatory bowel disease
10 Cytokine networks in the pathophysiology of inflammatory bowel disease
11 Role of chemokines in the pathophysiology of inflammatory bowel disease
12 Transforming growth factor (TGF)-β, activins and follistatin: A key regulator in inflammatory bowel disease 14 Role of Occludin, Claudin-2, and Zonulin in inflammatory bowel disease
Part B Immunotherapy in inflammatory bowel diseases
15 Basics of immunotherapy in inflammatory bowel disease
16 Targeting tumor necrosis factor (TNF)-alpha in inflammatory bowel disease
17 Integrin inhibition in inflammatory bowel disease
18 Janus kinase (JAK) inhibitors in inflammatory bowel disease
19 Stem cell and cell-based therapies in inflammatory bowel disease
20 Interleukin inhibition: targeting cytokine pathways
21 Key molecular targets for antisense therapy in inflammatory bowel disease
22 Therapeutic approaches targeting sphingolipids in inflammatory bowel disease
23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets
23 Tyrosine kinase inhibitors (TKIs) in inflammatory bowel disease: mechanisms and potential targets
24 Immune checkpoint modulation as a therapeutic strategy in inflammatory bowel disease
25 Potential targets for chimeric antigen receptor (CAR)-T cells in inflammatory bowel disease
26 Personalized medicine in inflammatory bowel disease immunotherapy
27 Advances in immunotherapy and emerging agents
28 Immunotherapy resistance and management of failure in inflammatory bowel disease
29 Safety, long-term outcomes, and side effects of immunotherapy
30 Immunotherapy and the gut microbiome in inflammatory bowel disease
Product details
Product details
- Edition: 1
- Latest edition
- Published: November 22, 2026
- Language: English
About the editors
About the editors
DM
Deepa S. Mandlik
Dr. Deepa S. Mandlik is an Associate Professor of Pharmacology with more than 18 years of experience in teaching, research, and academic administration. She is currently serving in the Department of Pharmacology at the Bharati Vidyapeeth (Deemed to be University) Poona College of Pharmacy, Pune, Maharashtra, India. Dr. Mandlik completed her Bachelor of Pharmacy (B. Pharm.) from the University of Pune, where she secured First Rank in the university. She subsequently obtained her Master of Pharmacy (M. Pharm.) in Pharmacology from the University of Pune and earned her Ph.D. in Pharmaceutical Sciences. An accomplished academician and researcher, Dr. Mandlik has published more than 88 research papers in reputed national and international peer-reviewed journals. Her research has received widespread recognition, with an h-index of 20 and more than 1,850 citations. She has authored more than seven pharmaceutical books and contributed over twenty book chapters published by internationally renowned publishers.
Dr. Mandlik is a recognized postgraduate and Ph.D. research supervisor. She has successfully guided several postgraduate and doctoral research scholars and has received research grants from various funding agencies in support of her scientific work. Her research interests encompass preclinical evaluation of herbal medicines, inflammation and immunology, cancer, diabetes, osteoporosis, rheumatoid arthritis and inflammatory bowel disease. Her work focuses on the development and pharmacological evaluation of novel therapeutic strategies and the translation of scientific discoveries into clinically relevant healthcare solutions. In addition to her research contributions, Dr. Mandlik has actively participated in curriculum development, academic administration, and professional training, contributing significantly to pharmaceutical education and research in India.
Affiliations and expertise
Bharati Vidyapeeth, Poona College of Pharmacy, IndiaSM
Satish Mandlik
Dr. Satish K. Mandlik is currently serving as an Associate Professor in the Department of Pharmaceutics at Bharati Vidyapeeth (Deemed to be University)'s Poona College of Pharmacy, Pune, Maharashtra, India. With over 18 years of teaching and research experience, he has made significant contributions to pharmaceutical education, research, and academic development. Dr. Mandlik completed his Bachelor of Pharmacy (B. Pharm.) from the University of Pune, securing Fourth Rank in the university. He obtained his Master of Pharmacy (M. Pharm.) in Quality Assurance from Goa University, where he was awarded First Rank for his outstanding academic performance.
An accomplished researcher and academician, Dr. Mandlik has published more than 50 research papers in reputed national and international peer-reviewed journals. His scholarly contributions have earned him an h-index of 17 with more than 1,450 citations, reflecting the quality and impact of his research. He has also authored more than Six Pharmaceutical books and contributed Eight international book chapters published by renowned publishers.
Dr. Mandlik is a recognized PG and Ph.D. Guide and his commitment to research has been recognized through research grants exceeding ₹8 lakhs received from various funding agencies.
His major research interests include nanotechnology-based drug delivery systems, targeted drug delivery, Quality by Design (QbD), Design of Experiments (DoE), pharmaceutical optimization techniques, formulation development, and pharmaceutical quality assurance. He has actively contributed to research in advanced drug delivery systems and pharmaceutical product development, with a focus on translating scientific innovations into practical healthcare solutions.
Affiliations and expertise
Department of Pharmaceutics, Poona College of Pharmacy Bharti Vidyapeeth Deemed University Pune, Maharashtra, India